Significant reduction in depressive symptoms among patients with moderately-severe to severe depressive symptoms after participation in a therapist-supported, evidence-based mobile health program delivered via a smartphone app.
Depression
Digital health interventions
ECT, electroconvulsive therapy
HRVB, heart rate variability biofeedback
ITT, intention-to-treat
MHP, Meru Health Program
Mobile health interventions
PHQ-9, Patient Health Questionnaire-9 item survey
Severe depression
TMS, transcranial magnetic stimulation
Journal
Internet interventions
ISSN: 2214-7829
Titre abrégé: Internet Interv
Pays: Netherlands
ID NLM: 101631612
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
15
09
2020
revised:
20
05
2021
accepted:
02
06
2021
entrez:
17
8
2021
pubmed:
18
8
2021
medline:
18
8
2021
Statut:
epublish
Résumé
Depression is a debilitating disorder associated with poor health outcomes, including increased comorbidity and early mortality. Despite the advent of new digital health interventions, few have been tested among patients with more severe forms of depression. As such, in an intent-to-treat study we examined whether 218 patients with at least moderately severe depressive symptoms (PHQ-9 ≥ 15) experienced significant reductions in depressive symptoms after participation in a therapist-supported, evidence-based mobile health (mHealth) program, Meru Health Program (MHP). Patients with moderately severe and severe depressive symptoms at pre-program assessment experienced significant decreases in depressive symptoms at end-of treatment (mean [standard deviation] PHQ-9 reduction = 8.30 [5.03], Hedges'
Identifiants
pubmed: 34401367
doi: 10.1016/j.invent.2021.100408
pii: S2214-7829(21)00048-8
pmc: PMC8350582
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100408Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
Dr. Forman-Hoffman is employed as the Chief Research Officer at Meru Health, Inc., receives salary from the company and owns options of the company. Dr. Nelson is an employee of Meru Health, Inc. Mr. Ranta serves as the Chief Executive Officer (CEO) at Meru Health, Inc., owns a large share of stocks, and raises salary from the company. Dr. Hilgert is employed as Director of Therapy Development and Clinical Operations at Meru Health Inc., receives salary from the company, and owns stocks and options of the company. Mr. Nazander serves as the Chief Technology Office (CTO) at Meru Health Inc., owns a large share of stocks, and raises salary from the company. Dr. de Quevedo has no competing financial interests.
Références
JAMA. 2010 Jan 6;303(1):47-53
pubmed: 20051569
Transl Psychiatry. 2019 Apr 3;9(1):127
pubmed: 30944309
NPJ Digit Med. 2019 Dec 2;2:118
pubmed: 31815193
Int J Soc Psychiatry. 2002 Sep;48(3):189-99
pubmed: 12413247
J Clin Psychiatry. 2013 Jun;74(6):595-602
pubmed: 23842011
Drug Saf. 2008;31(10):851-65
pubmed: 18759509
CNS Drugs. 2001;15(10):765-76
pubmed: 11602003
JAMA. 2012 Apr 18;307(15):1587-8
pubmed: 22511684
J Psychiatr Res. 2007 Apr-Jun;41(3-4):189-206
pubmed: 16870212
J Consult Clin Psychol. 1996 Jun;64(3):532-9
pubmed: 8698947
PLoS Med. 2008 Feb;5(2):e45
pubmed: 18303940
Transl Psychiatry. 2017 Mar 21;7(3):e1068
pubmed: 28323287
Arch Gen Psychiatry. 2005 Apr;62(4):409-16
pubmed: 15809408
Mov Disord. 2007 Sep 15;22(12):1722-8
pubmed: 17721929
Psychiatry Res. 2013 Dec 30;210(3):1260-4
pubmed: 24113125
World Psychiatry. 2017 Oct;16(3):287-298
pubmed: 28941113
Internet Interv. 2017 Jan 25;8:1-9
pubmed: 30135823
Behav Res Ther. 2017 Nov;98:4-18
pubmed: 27890222
J Clin Psychiatry. 2012 Oct;73(10):1287-91
pubmed: 23058983
JMIR Mhealth Uhealth. 2019 Aug 26;7(8):e14284
pubmed: 31452521
Health Aff (Millwood). 2014 Feb;33(2):194-9
pubmed: 24493760
Psychol Med. 2016 May;46(7):1459-72
pubmed: 26867988
J Affect Disord. 2010 Dec;127(1-3):122-9
pubmed: 20569992
Arch Gen Psychiatry. 1983 Feb;40(2):202-7
pubmed: 6337580
Psychotherapy (Chic). 2018 Dec;55(4):399-410
pubmed: 30335453
Neuropsychopharmacology. 2007 Jan;32(1):244-54
pubmed: 16936712
JAMA. 2003 Jun 18;289(23):3135-44
pubmed: 12813119
Dev Cogn Neurosci. 2018 Oct;33:83-98
pubmed: 29129673
Psychosom Med. 1999 Jan-Feb;61(1):6-17
pubmed: 10024062
J Affect Disord. 2004 Jul;81(1):61-6
pubmed: 15183601
Am J Psychiatry. 2006 Jan;163(1):28-40
pubmed: 16390886
Psychother Res. 2003 Mar;13(1):123-5
pubmed: 22475168
Lancet Psychiatry. 2015 Mar;2(3):271-4
pubmed: 26359904
Gen Hosp Psychiatry. 2004 May-Jun;26(3):184-9
pubmed: 15121346
JMIR Ment Health. 2019 Apr 12;6(4):e13202
pubmed: 30977736
Depress Anxiety. 2010;27(1):19-26
pubmed: 19798766
Ann Fam Med. 2010 Jul-Aug;8(4):348-53
pubmed: 20644190
J Clin Psychol. 2019 Jun;75(6):985-998
pubmed: 30702758
JMIR Form Res. 2019 Jan 22;3(1):e11509
pubmed: 30682726
J Am Geriatr Soc. 2009 Mar;57(3):506-10
pubmed: 19175438
Lancet Digit Health. 2020 Nov;2(11):e582-e593
pubmed: 33103097
J Affect Disord. 2008 Sep;110(1-2):1-15
pubmed: 18374988
Sleep. 2017 Apr 1;40(4):
pubmed: 28199710
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Br J Psychiatry. 2009 Aug;195(2):102-8
pubmed: 19648538
JAMA. 2013 Aug 14;310(6):591-608
pubmed: 23842577
Biol Psychiatry. 2003 Aug 1;54(3):216-26
pubmed: 12893098
BMJ. 2013 Feb 26;346:f540
pubmed: 23444423